Company ProfilePremium

Kazia Therapeutics Limited

Company Profile Analysis

Ticker: KZIA

ESOMAR 23 Corporate BadgeISO Certifications Badge
Kazia Therapeutics Limited - Company showcase

Year Founded & Workforce

1994

6 Employees

Kazia Therapeutics Limited logo

Kazia Therapeutics Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Kazia Therapeutics Limited Overview

Kazia Therapeutics is a Sydney-headquartered, Nasdaq-listed, clinical-stage oncology company. It in-licenses scientifically differentiated assets and develops them through partnered and investigator-led trials. Its value is concentrated in paxalisib, a brain-penetrant PI3K/Akt/mTOR inhibitor licensed from Genentech in 2016. Paxalisib carries FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations across glioblastoma, brain metastases, DIPG and AT/RT.

After paxalisib's GBM AGILE Phase 2/3 result in 2024 fell short of a clear registrational path, management repositioned the asset toward metastatic breast cancer. Early Phase 1b triple-negative breast cancer (TNBC) data in combination with pembrolizumab and chemotherapy showed an 83% objective response rate in six evaluable patients (August 2026), and an HR+/HER2- expansion followed.

Around paxalisib, Kazia has assembled an early immuno-oncology/epigenetics layer: NDL2 (an intracellular PD-L1 degrader) and MSETC (a SETDB1 inhibitor), both licensed from QIMR Berghofer. EVT801 (a VEGFR3 inhibitor from Evotec) remains a secondary clinical asset. Balance-sheet repair in 2025–26 transformed a going-concern situation into a funded, catalyst-rich micro-cap.


Company's own description

In its FY2025 Form 20-F, Kazia describes itself as an emerging, oncology-focused biotechnology company developing brain-penetrant and tumour-targeted small-molecule therapeutics. It names paxalisib and EVT801 as its principal product candidates. The FY2024 Directors' Report frames its principal activity as pharmaceutical research and development, with commercialisation of research results intended through license transactions "or other means."

From mid-2026, corporate boilerplate was updated. Kazia now describes itself as an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumour immunity and overcome treatment resistance (press releases, 27–31 August 2026). This signals a strategic rebranding from a "brain cancer company" to a "resistance-biology platform company."

Independent characterisation

Kazia is best characterised as a virtual, asset-centric drug developer:

Asset sourcing: It does not run discovery chemistry at scale. It acquires rights from large pharma (Genentech: paxalisib), European biotech (Evotec: EVT801) and Australian academic institutes (QIMR Berghofer: NDL2, MSETC).

Clinical execution: It relies heavily on cooperative groups, academic sponsors and platform trials, including GBM AGILE, Memorial Sloan Kettering, Dana-Farber, PNOC, the University of Sydney/COGNO (LUMOS2) and ANZCHOG (OPTIMISE). This capital-light model explains how a company with fewer than 15 staff has supported more than 15 paxalisib trials.

Monetisation: Kazia monetises regional rights through out-licensing. Examples are Simcere for Greater China (2021) and Sovargen for a rare-epilepsy indication (FY2024). Earlier, Oasmia licensed Cantrixil.

Revenue model

Revenue typeStatusEvidence
Product salesNone. The company has never generated product revenue20-F risk factors (FY2023, FY2025)
Licensing (upfront / milestones / royalties)Sole historical revenue source; irregularFY2021 A$15.18M (Simcere + Oasmia); FY2024 A$2.31M; FY2025 A$0.042M
Services / subscription——
Other incomeR&D tax incentive rebates; sundry income; fair-value gains on liabilitiesFY2025 R&D rebate A$209k, sundry income A$1.6M (20-F FY2025)

Value-chain position, customers and end-markets

Value-chain position: Upstream clinical development, from Phase 1 to Phase 2/3. Kazia has no manufacturing, sales force or distribution infrastructure.

"Customers" today: Licensees such as Simcere (China), Sovargen (South Korea) and Oasmia (Sweden). Prospectively, they are pharma partners for regional or global rights.

Ultimate end-markets (if approved): - Neuro-oncology: glioblastoma, brain metastases, DIPG/DMG, AT/RT, PCNSL

  • Metastatic breast cancer: TNBC, HR+/HER2-

  • Checkpoint-inhibitor-resistant solid tumours: NSCLC and breast (NDL2, MSETC)

  • Advanced solid tumours, including ovarian (EVT801)

Strategy

Stated strategy (themes from filings, AGM materials and 2026 releases)

  1. Reposition paxalisib beyond neuro-oncology. The H1 FY2026 report notes the company advanced paxalisib beyond neuro-oncology during the period. Breast cancer (TNBC, then HR+/HER2-) is now the primary value-driver, with enrichment via a proprietary epigenetic PI3K/mTOR biomarker (liquid and tissue tests).

  2. Preserve the GBM optionality. Kazia is pursuing discussions on a pivotal registrational GBM study for standard approval, following GBM AGILE.

  3. Build a "multi-layered" resistance-biology platform. Three layers: chromatin regulation (SETDB1/MSETC), immune checkpoint degradation (NDL2) and oncogenic signalling (paxalisib). Management describes this as addressing cancer across multiple layers of tumour biology (April 2026).

  4. Precision medicine and AI-guided discovery through the QIMR platform and the CSO's liquid/spatial epigenetic biomarker capabilities.

  5. Early partnering of preclinical assets (MSETC flagged for early strategic partnering).

  6. US capital-markets focus. ASX delisting, US-based CFO, and bulge/specialist bookrunners (Leerink, Guggenheim).

Initiative register (last 24 months)

DateInitiativeCategoryTargets / metrics
Jan 2025Advanced breast cancer trial (paxalisib + immunotherapy) approved and launchedClinical expansion—
Apr 2025ADS ratio change (1:500)Listing maintenanceNasdaq US$1 minimum bid
Jun 2025Phase 1b TNBC first patientClinical12 TNBC patients by end-2026 (Jan 2026 guidance); now enrolment complete July 2027 and expansion to 36
Oct 2025NDL2 in-licensePlatform / immuno-oncologyClinic by early 2027
Dec 2025US$50M PIPEFinancingEliminated going-concern overhang
Apr 2026SETDB1/MSETC platform in-licensePlatform / epigeneticsIND-enabling studies
Apr–Jun 2026CSO and CFO appointmentsLeadership—
Aug 2026Milestone-linked warrant financingFinancingSeries A tied to Stage IV TNBC readout (2H 2027); Series B tied to HR+/HER2- readout (1H 2028)
~Oct 2026HR+/HER2- three-arm expansion + provisional patentClinical / IPReadout 1H 2028

Medium-term financial targets. None. Kazia provides no revenue, EBITDA or profitability guidance. Its only quantitative guidance consists of clinical timelines.

ESG / sustainability commitments. No quantitative commitments disclosed.

Products & Services

Kazia has no marketed products. The catalogue below is the full development pipeline, organised by asset.

Paxalisib (formerly GDC-0084) — lead asset

AttributeDetail
MechanismOral, once-daily, brain-penetrant small-molecule inhibitor of the PI3K/Akt/mTOR pathway (dual PI3K/mTOR)
OriginLicensed from Genentech (Roche group), late 2016
Clinical footprintSubject of more than 15 clinical trials (company boilerplate, Aug 2026)
Regulatory designations (FDA)Orphan Drug — GBM (Feb 2018); Fast Track — GBM (Aug 2020); Rare Pediatric Disease + Orphan Drug — DIPG (Aug 2020); Rare Pediatric Disease — AT/RT (Jun 2022); Orphan Drug — AT/RT (Jul 2022); Fast Track — PI3K-mutated solid-tumour brain metastases with radiotherapy (Jul 2023)
Regional licenseesSimcere (Greater China: Mainland China, Hong Kong, Macau, Taiwan) — responsible for development, registration and commercialisation, with mid-teen royalties (AR 2022). Sovargen (South Korea) — rare epilepsy indication (FY2024)
IPLoss of exclusivity "no earlier than 2030 in any territory" (half-year report Dec 2022). New provisional patent (2026) on an epigenetic PI3K/mTOR biomarker in HR+ breast cancer
PricingNot applicable (pre-commercial)
IndicationTrial / sponsorPhaseStatus (latest disclosed)
Glioblastoma (newly diagnosed, MGMT-unmethylated)GBM AGILE (Global Coalition for Adaptive Research)Phase 2/3Completed; reported 2024. Kazia is in discussion on designing and executing a pivotal registrational study for standard approval (Aug 2026 boilerplate)
Stage IV metastatic TNBCKazia-sponsored, multi-centre, open-label, randomised Phase 1b (ACTRN12624001340527); paxalisib 30 mg daily + pembrolizumab + chemotherapyPhase 1bInitiated June 2025. Six evaluable patients: 1 CR, 4 PR, 1 SD (ORR 83%, CBR 100%). No paxalisib-related SAEs; no Grade ≥3 hyperglycaemia/stomatitis/mucositis (27 Aug 2026). Enrolment completion expected July 2027. Expansion planned from 12 to 36 patients (2026 6-K)
BRCA-mutated advanced breast cancerSame Phase 1b study — paxalisib + olaparib armPhase 1bOngoing; no efficacy data disclosed in sources reviewed
HR+/HER2- metastatic breast cancer (pre-treated, incl. CDK4/6-inhibitor-resistant)Three-arm expansion of the TNBC protocolPhase 1b expansionAnnounced ~1 Oct 2026, supported by preclinical resensitisation data. Readout expected 1H 2028 (per Series B warrant terms)
Brain metastases (with radiotherapy)Memorial Sloan Kettering Cancer Center (with two additional centres)Phase 1 (expansion cohort)Expansion cohort enrolling from 2023; ongoing
Diffuse midline glioma / DIPGPacific Pediatric Neuro-Oncology Consortium (PNOC022) and related studiesPhase 2Ongoing (boilerplate)
Primary CNS lymphomaInvestigator-led (Dana-Farber, per historic disclosures)Phase 2Ongoing (boilerplate)
IDH-mutant grade 2/3 gliomaLUMOS2 — University of Sydney / NHMRC CTC / COGNOPhase 2Supported since June 2023
Paediatric advanced solid tumours incl. brain tumoursOPTIMISE — ANZCHOGPhase 2Collaboration announced FY2023
AT/RTInvestigator studies / designationsEarlyRPDD + ODD granted 2022
Rare epilepsySovargen (licensee)Partner-ledLicensed FY2024

EVT801

AttributeDetail
MechanismSelective small-molecule inhibitor of VEGFR3 (anti-lymphangiogenic; tumour-microenvironment modulation)
OriginLicensed from Evotec SE, April 2021
Development stagePhase 1 in advanced solid tumours completed (FY2024 Annual Report), with encouraging results particularly in ovarian cancer
Milestone exposureUnbooked contingent milestones of €300.5M (A$456M) at 30 June 2022 (AR 2022, Note 16)
Current prioritySecondary; potential combination partner for NDL2 and paxalisib

NDL2 — intracellular PD-L1 protein degrader

AttributeDetail
ModalityBicyclic peptide degrader recognising post-translationally modified PD-L1 and recruiting cellular disposal machinery. Degrades PD-L1 across surface, cytoplasmic and nuclear compartments
OriginExclusive collaboration and in-licensing agreement with QIMR Berghofer, 7 Oct 2025. Inventor: Prof. Sudha Rao (now Kazia CSO)
Deal terms~US$1.39M one-time payment; Kazia bears all development costs; shares a percentage of commercialisation revenue, including out-licensing receipts (TheFly / company release)
Preclinical evidenceTumour growth reduction in aggressive TNBC models, as monotherapy and with anti-PD-1
Initial indicationsAdvanced breast cancer; non-small cell lung cancer
TimelineClinical entry targeted by early 2027 (ApexOnco/OncologyPipeline report)
Competitive noteDescribed by QIMR Berghofer as the most advanced PD-L1 degrader in development globally

MSETC — SETDB1 inhibitor and AI-integrated epigenetic platform

AttributeDetail
ModalityHighly selective bicyclic peptide targeting a disease-associated nuclear SETDB1 complex (not the isolated enzyme)
PlatformAI-integrated epigenetic drug-discovery engine developed at QIMR Berghofer; capable of generating follow-on candidates
DealLicense and Commercialisation Agreement signed 10 Apr 2026 (announced 13 Apr 2026). Exclusive, worldwide rights. ~US$1.39–1.4M upfront plus tiered revenue sharing aligned with development progress (BioWorld, Fierce Biotech)
RationaleRestore immune signalling in tumours resistant to checkpoint inhibitors
StagePreclinical; next milestone is IND-enabling studies, run in parallel with NDL2
StrategyFramed as a candidate for early strategic partnering

Divested / legacy assets

AssetStatus
Cantrixil (TRX-E-002-1; ovarian cancer)Out-licensed to Oasmia Pharmaceutical AB (Sweden) in FY2021: US$4M upfront, up to US$42M milestones, double-digit royalties.
Legacy Novogen consumer/isoflavone businessesDivested in earlier eras (pre-2016); details outside the 10-year window

Financial Narrative

Basis: IFRS consolidated statements; A$ millions unless stated. Sources: Annual Report / Appendix 4E FY2022 (FY2021–22 as originally reported), Form 20-F FY2024 (FY2022 restated, FY2023, FY2024), Form 20-F FY2025 (FY2023–25 net losses and FY2025 data), Half-Year Report 31 Dec 2025 (H1 FY2026).

Income statement

H1 FY2026 (six months to 31 Dec 2025), A$: loss after tax A$12.55M (H1 FY2025: A$10.45M); operating cash outflow A$9.54M (H1 FY2025: A$8.42M); other comprehensive loss A$0.86M.

Commentary. Kazia's P&L is a function of trial spending and deal timing. The FY2021 profile was flattered by US$11M of upfront licensing receipts (Simcere US$7M implied, Oasmia US$4M). In FY2022–FY2024, net losses of A$20–27M reflect peak spending on GBM AGILE, paediatric programmes and EVT801's Phase 1. The FY2025 R&D collapse to A$7.3M (from A$17.4M) was not strategic retrenchment by choice. It was forced by a liquidity crisis: cash fell to A$1.66M at June 2024 and the going-concern opinion followed in FY2025.

The H1 FY2026 loss of A$12.55M (versus A$10.45M) marks a re-acceleration of spending once the December 2025 PIPE closed. Expect FY2026 and FY2027 losses to rise materially as TNBC/HR+ trials expand and NDL2/MSETC move through IND-enabling work.

Balance sheet

Sources: AR 2022 Notes 9, 17, 18; 20-F FY2024 XBRL (cash series, GBM AGILE deposit); 20-F FY2023 (accumulated losses A$89.1M); edgar.tools/20-F FY2025 (total assets, liabilities); Half-Year Report Dec 2025 (net current liability at 30 June 2025). FY2025 equity is derived arithmetically: 6.06 − 14.36.

Position at 31 December 2025 (H1 FY2026):

  • Cash: A$69.46M

  • Net current assets: A$45.61M

  • Net assets: A$46.47M (turned positive from a deficit)

Debt. Kazia carries no conventional bank debt. Liabilities consist of trade payables, contingent consideration (EVT801 milestones assessed as probable), "other financial liabilities", a promissory note (FY2024 remeasurement gain A$25k) and a deferred tax liability. A short/long-term debt split, net debt and net debt/EBITDA are therefore not applicable. Net cash equals cash.

Goodwill and intangibles. Licensed assets (paxalisib, EVT801) are carried as separately acquired intangibles at cost and amortised (AR 2022, Note 2). Current carrying values were not captured in sources reviewed.

Cash flow

Change in cash is derived from year-end cash balances. FY2025 equity raised is per the 20-F FY2025 summary. Operating cash flow by full year was not captured; H1 FY2026 operating outflow was A$9.54M and H1 FY2025 was A$8.42M. Capex is immaterial for a virtual company and none was separately disclosed in sources reviewed. Free cash flow approximates operating cash flow.

Ratios

These are analyst-derived from the tables above. Runway = cash ÷ |net loss| and is a crude proxy, since net loss includes non-cash items.

Ratios not meaningful or not applicable:

  • ROE, ROA and ROIC: negative or NM, with equity negative at FY2025.

  • Current ratio: below 1.0x at FY2025 (net current liability A$9.12M). Sharply above 1.0x at December 2025.

  • Debt/equity, net debt/EBITDA, interest coverage: no funded debt.

  • Asset turnover: NM.

  • Cash conversion cycle: no inventory or receivables cycle.

Trend synthesis. Three phases are visible:

  1. FY2021 (licensing peak): cash A$27.6M, lowest loss.

  2. FY2022–FY2024 (investment phase): losses of A$20–27M per year, cash depleted to A$1.66M. Survival depended on remeasurement gains, deposits held by GBM AGILE and dribbling equity issues at heavily discounted prices.

  3. FY2025–H1 FY2026 (crisis and recapitalisation): going-concern doubt and a forced R&D cut, then the December 2025 PIPE and the August 2026 offering. Pro forma, Kazia likely holds well above US$80M in cash (A$69.5M at December 2025, less H2 FY2026 burn, plus ATM proceeds and ~US$37M net from August 2026). The exact current balance is not publicly disclosed as of this report.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionFunction (analyst interpretation)

Kazia Therapeutics Limited

NSW, Australia

Listed parent; holds licenses; R&D sponsor

Kazia Research Pty Ltd

Australia

Research subsidiary (likely R&D tax incentive vehicle)

Kazia Therapeutics Inc.

United States

US operations / clinical and investor presence

Glioblast Pty Ltd

Australia

Subsidiary (legacy/asset-holding; purpose not detailed in sources reviewed)

Revenue by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Pharmaceutical R&D — licensing revenue (AUD Mn)

15.18002.310.042

% contribution to total revenue

10000100100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

MetricFY2021FY2022FY2023FY2024FY2025

Loss after income tax (AUD Mn)

-8.42-25.01-20.47-26.78-20.70

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Revenue — licensing (AUD Mn)

15.18002.310.042

Other income (AUD Mn)

—0.0250.0010.173—

Finance income (AUD Mn)

—0.0020.0220.0120.072

R&D expenditure, company-sponsored (AUD Mn)

——15.617.47.3

Gain on remeasurement of contingent consideration (AUD Mn)

——3.3880.119—

Loss before income tax (AUD Mn)

-8.91-25.38-20.74-27.05—

Income tax benefit (AUD Mn)

0.480.370.270.27—

Net loss after tax (AUD Mn)

-8.42-25.01-20.47-26.78-20.70

Dividends per share (AUD)

00000

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Cash and cash equivalents (AUD Mn)

27.597.365.241.664.30

GBM AGILE deposit receivable (AUD Mn)

——3.753.76—

Total assets (AUD Mn)

————6.06

Total liabilities (AUD Mn)

————14.36

Shareholders' equity (AUD Mn)

————-8.30

Net current assets (AUD Mn)

————-9.12

Deferred tax liability — licensing (AUD Mn)

2.932.56———

Contributed equity (AUD Mn)

80.2984.48———

Accumulated losses (AUD Mn)

——89.1——

Balance Sheet — Change in cash

MetricFY2021FY2022FY2023FY2024FY2025

Change in cash (AUD Mn)

—-20.23-2.12-3.582.64

Equity raised from ADS sales (AUD Mn)

————16.0

Capital expenditure (AUD Mn)

00000

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Instrument by Date

DateInstrumentGrossNet / notes

Oct 2020

ANREO placement + retail at A$0.80

A$16.4M institutional + retail

AR 2022

FY2023

Placement + Share Purchase Plan

A$7.106M

AR 2023

Feb–May 2025

F-1 registered offering (No. 333-284606)

Not captured

Prospectus 5 Feb 2025

FY2025 total

ADS sales

A$16.0M

20-F FY2025

2 Dec 2025

PIPE (private placement)

~US$50.0M

~US$46.5M net (Half-Year Report). BioWorld reported "AU$50M (US$33.15M)" — conflicting with the company's US$ figures; the company figure is preferred

H2 FY2026

New at-the-market (ATM) program

—

StockTitan summary of 6-K, Mar 2026

28–31 Aug 2026

Tranched registered offering (F-3 No. 333-294392): 2.58M ADSs or pre-funded warrants + Series A and Series B warrants

US$40M upfront

Up to US$80M additional if warrants are fully exercised

“—” = not publicly disclosed.

Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

Net loss / average cash (x)

—1.443.297.797.03

Cash runway at year-end FY loss rate (years)

3.280.290.260.060.21

Revenue by Region

Region (licensee country)FY2021FY2022FY2023FY2024FY2025

China — Simcere (AUD Mn)

10.010000

Sweden — Oasmia (AUD Mn)

5.180000

South Korea — Sovargen (AUD Mn)

0002.310

Unallocated / not disclosed (AUD Mn)

00000.042

Total (AUD Mn)

15.18002.310.042

Capital Markets

MeasureValueSource / date

Recent price

10.56 (intraday)

Yahoo Finance, ~21 Sep 2026

52-week range

4.86 – 17.40

Yahoo / Google Finance

YTD 2026 total return

+63.39%

Yahoo, as of 21 Sep 2026

1-year total return

+36.02%

Yahoo, as of 21 Sep 2026

3-year and 5-year return

Deeply negative (market cap fell to ~US$4–10M in September–October 2025; two reverse ADS ratio actions).

TipRanks history

Offering price reference

15.50 combined (28 Aug 2026)

Pricing release

Market Valuation

Metric2025-092025-102026-032026-042026-072026-09

Market cap (USD Mn)

4.29.781.5109.1151.9120.6

Valuation Multiples

MultipleKaziaComment

EV (illustrative)

Market cap less cash (likely US$80M+ pro forma) suggests a low EV, possibly US$50–70M. Not computed precisely because current cash is undisclosed

Analyst judgement

Analyst Ratings & Targets

BrokerAnalystRatingPrice target (USD)Date

BTIG

Kambiz Yazdi

Buy

34

15 Jul 2026

Lake Street

Chad Messer

Buy (initiation)

32

11 Jun 2026

Maxim Group

Naz Rahman

Buy

30

15 Jul 2026

H.C. Wainwright

Sean Lee

Buy

182026

Consensus

—

Strong Buy / Buy (4–6 analysts)

28.50 – 28.87 average

Google Finance; Yahoo (Sep 2026)

Capital Markets — Dividend history / policy

ItemStatus

Dividend history / policy

None paid in FY2021–FY2025; no dividend policy (Appendix 4E FY2022; 20-F)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

No funded debt

Outstanding derivative equity

Series A warrants: up to 2,243,478 ADSs at US$17.825. Series B warrants: up to 2,064,000 ADSs at US$19.375. Pre-funded warrants (number not disclosed). Prior-round warrants likely outstanding from the PIPE (terms not captured)

Analyst Conclusions

Management guidance (clinical, not financial)

ItemGuidanceSource
TNBC Phase 1b enrolmentCompletion by July 2027, with interim updates throughout 2026–27 (earlier guidance: 12 patients by end-2026, topline early 2027)27 Aug 2026 release; 27 Jan 2026 release
Stage IV TNBC data readoutExpected 2H 2027 (Series A warrant trigger)28 Aug 2026 pricing release
HR+/HER2- data readoutExpected 1H 2028 (Series B warrant trigger)Same
NDL2 clinical entryEarly 2027ApexOnco report on company statements
MSETCIND-enabling studies; early partnering13 Apr 2026 release
GBMDesign of pivotal registrational study under discussionCorporate boilerplate
Financial guidanceNone issued—

Consensus growth expectations. Revenue consensus is not meaningful. Sell-side targets (US$18–34) imply 70–220% upside from ~US$10.56, reflecting probability-weighted breast cancer value.

Bull case

  1. Breast cancer data scale: if ORR remains above 50% and the tolerability edge persists as the TNBC cohort grows from 6 to 36, paxalisib becomes a credible add-on to the pembrolizumab + chemotherapy backbone. It would also gain strategic relevance to Merck-centric combination strategies.

  2. HR+/HER2- resensitisation validated: a biomarker-enriched population in a segment of 60–70% of breast cancers, with an oral, brain-penetrant agent, could support a pharma partnership worth multiples of today's ~US$120–150M market cap. Warrant exercise would add up to US$80M.

  3. Platform optionality is cheap: two first-in-class preclinical assets cost under US$3M upfront combined. Any NDL2 IND clearance or MSETC partnering would be accretive against a low enterprise value.

Bear case

  1. Small-n mirage: six patients, single-arm, with expanded-access anecdotes. PI3K/mTOR toxicity and response durability may disappoint at scale, as many PI3K programmes have historically.

  2. Crowded field and partner scepticism: three approved PI3K/AKT agents plus gedatolisib in Phase 3 mean Kazia must show clear differentiation to command a deal. GBM remains unpartnered after GBM AGILE.

  3. Execution and governance fragility: a ~6-person company with a three-member board, recurring dilution (two ADS ratio changes in six months, ATM in place) and readouts in 2H 2027 / 1H 2028 faces long cash-burn periods. Warrant capital is contingent and may never arrive.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Q4 2026Interim TNBC updates (n>6); HR+ arm activation; possible conference presentations (subject to IP strategy)
Q4 2026 – Q1 2027Appointment of a permanent Chair and board expansion
Nov 2026 (est.)FY2026 Form 20-F: full-year loss, cash, going-concern language (expected to be removed)
Early 2027NDL2 IND/CTN filing and first-in-human start
H1 2027Half-year report; burn rate post-expansion
2,027GBM registrational study decision and FDA alignment; any partnering (MSETC, regional paxalisib rights)
OngoingATM usage and dilution; warrant overhang dynamics versus US$17.825 / US$19.375 strikes; Nasdaq compliance

Concluding analyst verdict

Kazia Therapeutics has executed one of the more striking micro-cap turnarounds in Nasdaq-listed Australian biotech. In under twelve months it went from a going-concern warning with A$4.3M cash and a market value near US$4M (September 2025) to a recapitalised company. It held A$69.5M in cash at December 2025, raised a further ~US$40M upfront in August 2026, and enjoys broad Buy-rated sell-side coverage.

The turnaround rests on a strategic pivot. Paxalisib, a once neuro-oncology-only asset whose GBM AGILE outcome failed to deliver a direct approval route, has been redeployed into metastatic breast cancer. There, early data are eye-catching: an 83% ORR and 100% CBR in six Stage IV TNBC patients without the hallmark PI3K toxicities. Around it, management has bolted on two inexpensive, first-in-class preclinical platforms from QIMR Berghofer and brought their inventor in as CSO.

The investment case, however, remains a binary, data-dependent proposition with a long fuse. The decisive readouts (TNBC in 2H 2027, HR+/HER2- in 1H 2028) are 12–20 months away, and the financing structure explicitly ties incremental capital to them. Six patients is not a dataset. The PI3K-pathway breast cancer market is crowded with large-pharma incumbents, and the company's operational and governance bench is extremely thin for the ambitions now articulated.

Verdict: Speculative positive / high risk. The asymmetry is genuine: a low enterprise value relative to cash, warrant-aligned financing and multiple shots on goal. But expected value hinges on replication of the TNBC signal at n=36 and on credible HR+ differentiation.

Key watch items: interim breast cancer updates, board reinforcement, FY2026 20-F cash disclosure, and NDL2's entry into the clinic. Failure on any of the first two would likely re-rate the equity sharply lower given the dilution history.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / educationSource

Dr John Friend, B.A., M.D.

Chief Executive Officer; Managing Director

CEO since 1 May 2023 (previously Chief Medical Officer); MD since 1 Aug 2023; Interim Chair 11 Aug 2023 – 18 Jan 2024

US-trained physician; practised medicine in North Carolina. Roughly 15 years in oncology/haematology drug development across start-ups and multinationals

Annual Report 2023; FY2024 Directors' Report

James Levine

Chief Financial Officer

Since 1 Jun 2026

CFO, Cardiff Oncology. CFO, Cidara Therapeutics (structured the US$568M Mundipharma licensing and US$780M Janssen partnership). CEO, Verenium (~US$200M asset sales). CEO, Sapphire Energy. 12 years at Goldman Sachs as Managing Director in healthcare

Press release, 2 Jun 2026

Prof. Sudha Rao

Chief Scientific Officer

Since 15 Apr 2026

Leads the Gene Regulation and Translational Medicine Laboratory at QIMR Berghofer. Former senior scientist at Sanofi/Rhône-Poulenc (UK). Lead inventor on 39 international patents. Inventor of NDL2 and MSETC

Press release, 15 Apr 2026

Karen Krumeich

Former CFO

Appointed c.2023–24; succeeded by Levine (June 2026)

Departure date and context not disclosed in sources reviewed

Quantisnow headline archive

Anna Sandham

Company Secretary

—

BEc, Grad.Dip.AppCorpGov, FGIA

Annual Report 2023

Board of Directors

NameRoleTenureBackground

Dr John Friend

Managing Director & CEO (executive)

Board since Aug 2023

As above

Steven Coffey

Non-Executive Director

Pre-2023; re-elected at AGM 25 Mar 2026 (1,050,412,780 votes for)

Background details not captured in sources reviewed

Ebru Davidson

Non-Executive Director; member, Audit, Risk & Governance Committee (from 31 Mar 2026)

Since 5 Jun 2023

Corporate lawyer; General Counsel, QBiotics Group

Bryce Carmine

Former Chairman

Director 2015 – 31 Mar 2026; Chair 18 Jan 2024 – 31 Mar 2026

Ex-Eli Lilly: President, Global Pharmaceutical Product Development; EVP/President Established Markets 2010–12; President, Lilly Japan 1995–99

Robert Apple

Former Non-Executive Director

Appointed 15 Jan 2024; departure date not captured

Former Antares Pharma board member (2016–May 2022); prior boards include InKine, PaxMedica, Kerathin

Iain Ross

Former Chairman

Chair c.2015 – 11 Aug 2023

—

Dr James Garner

Former CEO & MD

c.2016 – May 2023

Led Novogen-to-Kazia transformation; in-licensed paxalisib and EVT801

Major Shareholders

Holder categoryDetail

Top 10 institutional holders

Not publicly disclosed in sources reviewed. 13G filings exist historically; the December 2025 PIPE and August 2026 offering (Leerink/Guggenheim-led) likely introduced specialist healthcare funds.

Insider ownership

Low. Example: Bryce Carmine held 856,681 ordinary shares (~0.01%) as of September 2025 (MarketScreener)

ADS vs ordinary

Following the ASX delisting, nearly all trading occurs via ADSs (1:500)

Competitive Landscape

Competitors by Segment

ProgrammeCompetitorAsset / approachPositioning vs Kazia

GBM

Novocure

Optune (tumour treating fields), marketed

Established standard adjunct; Kazia would be additive

GBM / glioma

Servier

Vorasidenib (IDH1/2 inhibitor; approved 2024 for IDH-mutant glioma)

Different molecular segment (IDH-mutant vs unmethylated GBM)

DMG/DIPG

Jazz Pharmaceuticals (acquired Chimerix, 2025)

Dordaviprone (ONC201)

Approved for H3 K27M DMG (2025); raises bar in DIPG

Paediatric glioma

Day One Biopharmaceuticals

Tovorafenib (Ojemda), marketed

BRAF-altered pLGG; adjacent

GBM

CNS Pharmaceuticals, Plus Therapeutics, Telix

Berubicin; radiotherapeutics; TLX101

Micro/small-cap peers in recurrent GBM

PI3K pathway, breast

Novartis

Alpelisib (Piqray)

PIK3CA-mutant HR+; hyperglycaemia limits use. Kazia claims cleaner tolerability

PI3K/AKT, breast

AstraZeneca

Capivasertib (Truqap)

Approved HR+/HER2- with PIK3CA/AKT1/PTEN alterations

PI3Kα, breast

Roche

Inavolisib (Itovebi)

Approved first-line PIK3CA-mutant HR+

PI3K/mTOR, breast

Celcuity

Gedatolisib (IV pan-PI3K/mTOR)

Closest mechanistic analogue in HR+/HER2-; ahead in Phase 3

Mutant-selective PI3Kα

Relay Therapeutics; Eli Lilly (via Scorpion asset acquisition)

RLY-2608; STX-478

Next-generation, mutant-selective, lower hyperglycaemia

TNBC immunotherapy

Merck; Gilead; AstraZeneca/Daiichi Sankyo

Pembrolizumab (backbone); sacituzumab govitecan (Trodelvy); datopotamab deruxtecan

Kazia positions as add-on to the pembro + chemo backbone

PD-(L)1 next-gen

Summit/Akeso; BioNTech; others

PD-(L)1 x VEGF bispecifics

Alternative route to checkpoint resistance; NDL2 is the only clinical-track degrader per QIMR

VEGFR3 / lymphangiogenesis

Various (no direct clinical-stage selective VEGFR3 peer identified)

—

EVT801 differentiated but low priority

Peer Comparison FY2025

CompanyLatest FY revenue (USD Mn)GrowthProfitabilityR&D intensityStage

Kazia Therapeutics (FY2025, A$)

0.03 (A$0.042M)

−98%

Net loss A$20.7M

R&D A$7.3M; NM %

Phase 1b–3

Novocure (FY2024)

——

Loss-making

High

Commercial

Celcuity (FY2024)

0 (pre-revenue)

—

Loss-making

—

Phase 3

Day One Biopharmaceuticals (FY2024)

—

Launch year

Loss-making

High

Commercial

Recent Developments

--

Company Snapshot

6

Employees

$120.6M

Market Cap

1994

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Clinical signal in TNBC: CBR 100% and ORR 83% (1 CR + 4 PR of 6) with no paxalisib-related SAEs (27 Aug 2026).
  • Regulatory designations: six FDA designations across GBM, DIPG, AT/RT and brain metastases (2018–2023).
  • Balance sheet restored: cash rose from A$1.66M (June 2024) to A$69.46M (December 2025), plus ~US$40M gross raised in August 2026.
  • Low-cost pipeline expansion: NDL2 and MSETC acquired for ~US$1.4M upfront each (Oct 2025, Apr 2026).
  • Brain penetration: differentiates paxalisib from approved PI3K agents in breast cancer patients with CNS disease (Fast Track for brain metastases, July 2023).
  • Strengthened leadership: a CFO with US$1.3B+ of partnership structuring experience (Cidara) and a CSO who invented the platform (2026).

Weaknesses

  • Small datasets: efficacy claims rest on six evaluable patients plus expanded-access cases.
  • No recurring revenue: FY2025 revenue was A$42k, down 98% YoY.
  • Recent going-concern history: substantial doubt disclosed in the 20-F FY2025 (Nov 2025); runway was then to ~March 2026.
  • Governance thinness: three-director board after March 2026; Chair vacancy unresolved in sources reviewed.
  • Very small organisation: ~6 employees (Google Finance), making execution dependent on partners.
  • Shareholder dilution and value destruction: two ADS ratio changes (Oct 2024, Apr 2025); 809M ordinary shares at June 2025, materially more since.

Opportunities

  • HR+/HER2- expansion: largest breast cancer segment, with a CDK4/6-resistance resensitisation hypothesis and a biomarker patent (~Oct 2026).
  • Warrant inflows: up to US$80M of non-dilutive-at-the-margin cash if TNBC/HR+ data are positive (Aug 2026 terms).
  • Priority review voucher potential: RPDD for DIPG and AT/RT if paediatric approval occurs.
  • NDL2 first-in-class status: most advanced PD-L1 degrader; clinic targeted by early 2027.
  • GBM registrational pathway discussions offer standard-approval optionality (boilerplate, Aug 2026).
  • Partnering potential: MSETC is explicitly earmarked for early partnering; Simcere/Sovargen precedents show demand for regional rights.

Threats

  • Competition in PI3K-pathway breast cancer from capivasertib, inavolisib, alpelisib and gedatolisib (Phase 3).
  • Approval of dordaviprone for H3 K27M DMG (2025) raises the bar in DIPG.
  • Class toxicity at larger n: hyperglycaemia and stomatitis typical of PI3K/mTOR could emerge as enrolment grows to 36+.
  • Financing dependence: if readouts slip, warrants expire unexercised; an ATM overhang remains.
  • Nasdaq listing fragility: history of bid-price deficiencies (Nov 2023 notice).
  • Licensor milestone burden: e.g., €300.5M of unbooked EVT801 milestones (AR 2022) and revenue shares with QIMR reduce Kazia's economic share.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
17 Apr 2025ADS ratio change from 1:100 to 1:500 takes effect (1,359,625 ADSs outstanding immediately after)Second reverse-ratio action in six months; preserves Nasdaq listing
15 May 20256-K and 424B3 supplement to the F-1 (274,666 ADSs)Continued small-scale dilutive funding
Jun 2025First TNBC patient (61-year-old, lung-involved metastatic TNBC) starts paxalisib 30 mg + pembrolizumab + gemcitabine/carboplatinStart of the programme that now drives valuation
Jun 2025Phase 1b advanced breast cancer study formally initiated (pembro + chemo arm; olaparib arm for BRCA-mutated)Platform for TNBC/HR+ expansions
Mid–late 2025Kazia reports significant tumour reduction in a TNBC patient; Maxim raises price target from US$15 to US$20 (TheFly headlines)First clinical signal; analyst support
Sep 2025Market cap trough of ~US$4.2–4.6M (TipRanks history)Existential distress; equity priced for failure
7 Oct 2025NDL2 PD-L1 degrader in-license from QIMR BerghoferPivot toward immuno-oncology platform
Oct 2025Files to register resale of 232,956 ADSs for holdersOverhang
7 Nov 2025FY2025 20-F: net loss A$20.7M; cash A$4.3M; going-concern doubt; runway to ~March 2026; baby-shelf limitsPeak financial risk disclosure
2 Dec 2025~US$50M PIPE priced (~US$46.5M net)Transformational recapitalisation
Dec 2025 – Mar 2026Preclinical data on nuclear PD-L1 degrader NDL-2 reported (BioWorld)Supports NDL2 IND path
27 Jan 2026TNBC update: 2 of 2 evaluable Phase 1b patients with PR; one confirmed complete metabolic response (expanded access); target 12 TNBC patients by end-2026, topline early 2027Credibility for breast repositioning
16 Mar 2026Half-year results: loss A$12.55M; cash A$69.46M; net assets A$46.47M; new ATM programBalance sheet restored
25 Mar 2026AGM: Steven Coffey re-electedGovernance continuity
27 Mar 2026Investor presentation and fact sheet furnishedStrategy articulation
26–31 Mar 2026Chair Bryce Carmine retires; Board shrinks to three; Davidson joins Audit, Risk & Governance CommitteeGovernance thinning; no disagreement cited
10–13 Apr 2026SETDB1/MSETC platform in-license (~US$1.4M upfront)Third pipeline layer
15 Apr 2026Prof. Sudha Rao appointed CSOInventor of platform assets joins management
2026 (mid)6-K: TNBC Phase 1b expansion from 12 to 36 patients; abstracts withdrawn for IP reasons; updates throughout 2026–27Larger, more informative dataset; timeline extended
2 Jun 2026James Levine appointed CFO (effective 1 June)Deal-making and financing credentials
11 Jun 2026Lake Street initiates at Buy (PT US$32)Broadening coverage
15 Jul 2026Maxim reiterates Buy (PT US$30); BTIG maintains Buy (PT US$34)Sell-side momentum
27 Aug 2026Six evaluable Stage IV TNBC patients: CBR 100%, ORR 83% (1 CR, 4 PR), durable CMR since Nov 2025; enrolment completion July 2027Key de-risking datapoint (small n)
28 Aug 2026Prices tranched offering: combined price US$15.50/ADS; Series A warrants at US$17.825 and Series B at US$19.375, expiring 30 days after the respective readoutsMilestone-contingent financing aligns capital with data
31 Aug 2026Offering closes oversubscribed (~US$40M gross upfront); corporate update call 1 Sep 2026Funding through key 2027 readouts
2026Form 3 filed for director Ebru DavidsonGovernance/reporting change
~1 Oct 2026HR+/HER2- expansion (three arms) and provisional patent; preclinical data show resensitisation of CDK4/6-inhibitor-resistant tumoursExpands addressable market roughly 5–6x versus TNBC

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Pharmaceutical R&D — licensing revenue fell from AUD 15.2 Mn in FY2021 to AUD 0 Mn in FY2025.
Kazia Therapeutics Limited — Revenue by Segment
Series (AUD Mn)FY2021FY2022FY2023FY2024FY2025
Pharmaceutical R&D — licensing revenue15.2002.30
% contribution to total revenue10000100100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.